Speaker illustration

Doctor Rodrigo Modolo

Boston Scientific Corporation, Maple Grove (United States of America)

Member of:

European Society of Cardiology

Dr. Modolo is a cardiologist and interventional cardiologist by training. Obtained his MD in 2005, his PhD in 2014 and conclude an over 2-year research fellowship in Interventional Cardiology with the Academic Research Team of Prof Patrick W. Serruys in Rotterdam, Netherlands. He has author/co-authored over 120 scientific publications indexed on PubMed. Has mentored MSc and PhD students. Currently he is the Medical Director for Structural Heart at Boston Scientific in the United States. Main interests are in TAVI, new devices in interventional cardiology, antiplatelet therapy following PCI and treatment for 3-vessel disease and left main disease (PCI vs. CABG).

Potential benefit of ticagrelor monotherapy for patients with hypertension undergoing percutaneous coronary intervention: Insights from the Global Leaders trial

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Acute Coronary Syndromes - Treatment antiplatelet


Clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: A sub-analysis of the SYNTAX II study

Event: ESC Congress 2018

Topic: Technique

Session: Coronary interventions - Stents


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb